Solana's network is attracting new users at a rapid pace, adding over 10 million first-time transaction addresses daily. However, conflicting signals from ETF outflows and a cautious macro environment are testing whether this growth can fuel a sustained price rally for SOL.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Real Matters Inc. (TSE: REAL) kicked off its 2026 fiscal year with robust double-digit revenue growth and a return to profitability, defying typical seasonal headwinds. The company's performance was fueled by market share gains, new client launches, and improved operational efficiency across its U.S. and Canadian segments.
Exco Technologies Ltd. (TSE:XTC) kicked off its fiscal 2026 with a solid first quarter, posting higher profits despite a mixed demand environment. Robust growth in its Automotive Solutions segment successfully countered softer demand in its die-cast tooling business, showcasing the resilience of its diversified model amid ongoing trade policy and economic uncertainty.
Waste Management capped off a strong 2025 with record cost performance and margin expansion, driven by operational discipline and its growing sustainability portfolio. The company forecasts continued growth for 2026, backed by robust cash flow and ambitious capital return plans.
While market volatility rattles investors, Volvere plc (LON:VLE) has quietly engineered a remarkable three-year run, with its share price soaring 148%. We examine the fundamentals behind the surge and ask if the momentum can hold.
Bitcoin's volatility gauge spiked sharply during Thursday's sell-off, signaling heightened trader anxiety and a rush for downside protection, though metrics suggest the market is not yet in extreme fear territory.
A new industry report reveals Latham & Watkins advised on a record $370bn in tech, media, and telecom deals last year, narrowly edging out rivals in a highly competitive legal advisory market.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
President Trump is expected to nominate former Fed governor Kevin Warsh as Jerome Powell's successor, a move markets interpret as a tilt toward more hawkish monetary policy and an end to months of uncertainty over the central bank's leadership.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
The utility giant Southern Company has declared its latest quarterly dividend, preserving one of corporate America's most remarkable records of shareholder returns. As markets fluctuate, the company's steady income stream and undervalued stock price are drawing renewed attention from long-term investors.
German industrial giant Thyssenkrupp is exploring the sale of a significant minority stake in its Rothe Erde bearings division, a move analysts say could signal a broader portfolio reshuffle and highlight persistent valuation gaps within the conglomerate.
Krones AG (ETR:KRN) has seen its stock price climb 11% in the past quarter. Analysis points to robust fundamentals, particularly a healthy Return on Equity (ROE) of 14%, as a key driver behind the market's bullish sentiment and the company's impressive earnings growth trajectory.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Analysts at Stifel have initiated coverage on sports data giant Sportradar Group AG (NASDAQ: SRAD) with a Buy rating and a $28 price target, citing its dominant market position and favorable industry dynamics as online sports betting consolidates.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
